Increased Recovery and Survival in Patients With COVID-19 Respiratory Failure Following Treatment with Aviptadil: Report #1 of the ZYESAMI COVID-19 Research Group-Reference-Cited by-同舟云学术

Increased Recovery and Survival in Patients With COVID-19 Respiratory Failure Following Treatment with Aviptadil: Report #1 of the ZYESAMI COVID-19 Research Group

Published:2021 Issue: Volume: Page:
ISSN:1556-5068
Container-title:SSRN Electronic Journal
language:en
Short-container-title:SSRN Journal

Author:

Youssef Jihad G.,Lee Richard,Javitt Jonathan,Lavin Philip,Lenhardt Rainer,Park David J,Perez Fernandez Javier,Morganroth Melvin,Jayaweera Dushyantha

Publisher

Elsevier BV

Reference27 articles.

1. Potent peripheral and splanchnic vasodilator peptide from normal gut;S I Said;Nature,1970

2. Vasoactive Intestinal Peptide Receptor Scintigraphy;I Virgolini;J Nucl Med,1995

3. Vasoactive intestinal peptide in the lung;S I Said;Ann NY Acad Sci,1988

4. VIP as a modulatory of lung inflammation and airway constriction;S I Said;Am Rev Respir Dis,1991

5. Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide;S I Said;Regul. Pept,2000

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial;Trials;2022-09-20

2. VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells;Journal of Leukocyte Biology;2022-03-24

3. VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells;2020-07-26